BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that results of its pivotal MARINE Phase 3 clinical trial were published in the September issue of The American Journal of Cardiology. The Company also reported, as previously announced, that data from the Company's Phase 3 MARINE trial was presented at the European Society of Cardiology (ESC) Congress 2011.
